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Abstract
Radiotherapy is a cornerstone of the modern treatment of many types of 
cancer, having both curative and palliative roles. It is estimated that more than 
half of cancer patients will need radiation therapy in the course of evolution. The 
goal of radiotherapy is to maximize tumor control, reducing adverse effects on 
normal tissues in close proximity at the same time. Improving the therapeutic 
ratio is the main goal of the efforts made to improve the technique and accuracy 
of the radiotherapy by using the targeting of the tumor volume with the help of 
the imaging guide and the dose conformation around the target volume. The use 
of the multi-leaf collimator (MLC) allowed a better coverage of the target volume 
in the irradiation field, thus reducing the unnecessary irradiation of healthy tis-
sues. The use of radioprotective agents and radiosensitizers is another strategy to 
maximize the effect of radiotherapy. Recently, interest has focused on the design 
of irradiation protocols that exploit the differences in biology in terms of the 
response to irradiation between tumor cells and normal tissues.
Keywords: radiotherapy, IMRT, VMAT, SIB, dosimetry
1. Introduction
The transition in the 1990s from conformal 3D radiotherapy to intensity-modu-
lated intensity radiotherapy (IMRT) allowed the high-dose irradiation of volumes 
with irregular shapes [1, 2]. The use of radioprotective agents and radiosensitizers 
is another strategy to maximize the effect of radiotherapy. Recently, interest has 
focused on the design of irradiation protocols that exploit the differences in biology 
in terms of the response to irradiation between tumor cells and normal tissues [2, 3].
From the clinical point of view, tissue radiosensitivity is reported as the differ-
ence in the degree of response at the same dose of irradiation or at different doses 
required to produce the same response to different subjects. The radiosensitivity 
and radioresistance of the different types of tissues is determined by the mitotic rate 
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and the cellular repopulation, being proven that the cells with low rates of repopu-
lation are more radioresistant. Especially for cells with long post-mitotic life, for 
which the main mechanism of radiation induced hypoplasia and atrophy, is death in 
interphase, the response is obtained only at high doses of radiation [1, 2, 4].
With all the technical and ballistic advances in the planning and delivery of 
radiation therapy that has occurred in over 100 years since the use of radiation 
in anticancer treatments, it has not been possible to obtain a perfect therapeutic 
ratio for which the irradiation of healthy tissues tends to zero. Historically, the 
first initiative to guide doctor radiation oncologists was the publication of Rubin 
and Cassarett, a collection of reports on toxicities and doses to which they were 
reported. The 1980s were a significant evolution in the field of radiation oncology, 
the radiotherapy being transformed from a two-dimensional (2D), based on the 
approximate evaluation of the position of the radiosensitive organs based on the 
anatomical landmarks and subsequently of the 2D simulator with conventional 
radiographs, to a three-dimensional (3D/volumetric) process. This evolution has 
shown that previous knowledge about tumoricidal doses and tolerance of radio-
sensitive organs to irradiation does not present accuracy and new information is 
needed regarding partial organ volumes and toxicities [2, 5].
In this context, a scientific committee has carried out an extensive review on 
the dose data received from different organs and toxicities, reaching the con-
sensus to evaluate the data using a volumetric division of organs in one-third, 
two-thirds, and the whole organ. The consensus of eight experts from reference 
centers in the United States was published under the name “Emami Paper.” The 
paper was a reference for assessing the risk of toxicity associated with doses, but 
being a literature review until 1991, it contained data from the previous 3D-CRT 
technology. Another limitation of the study was the evaluation of toxicities after 
conventional irradiation (2 Gy/fraction), and at that time neither the dose-
volume histograms were routinely used in dosimetry. From the clinical point of 
view, only the most severe toxicity was evaluated, without any grading system for 
these adverse effects [1, 2, 6, 7].
The next decades have brought a revolution in terms of oncological treatments. 
A multidisciplinary approach has become a standard in oncology, and sequential 
and increasingly concomitant therapeutic associations are increasingly used. In 
terms of technology, most cobalt units have been replaced with linear accelerators, 
and radiotherapy planning based on CT simulation has become standard. 3D-CRT 
and IMRT techniques based on IGRT have been widely implemented, and delinea-
tion of tumor target volumes using CT, MRI, and PET-CT imaging has become 
a standard. The complexity and the large number of factors that influence the 
response to the irradiation of the tumors and the probability of the complications 
of the normal tissues have made it necessary to develop predictive models for the 
clinical complications associated with the radiation therapy. The large number of 
data reported in relation to the different toxicities and conditions of registration 
make analysis difficult to identify value parameters. A group of clinicians and 
researchers performed a retrospective analysis called “Quantitative Analysis of 
Normal Tissue Effects in the Clinic (QUANTEC).” The aim of this approach was to 
review the available literature on the correlation of dose-volume parameters with 
the complications of normal tissues, the study being the analysis of the literature 
of the last 18 years. The paper QUANTEC, resulting from the collective effort of 
57 experts, appears with the support of the American Association of Radiation 
Therapy (ASTRO) and American Association of Medical Physics (AAPM) and 
is published in the supplement of the journal “International Journal of Radiation 
Oncology, Biology, Physics” (the Red Journal) [2, 5–8].
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The QUANTEC group aimed to provide a reliable prediction at the time of radio-
therapy planning of the risk of occurrence of toxicity depending on the volume 
parameters extracted from the dose-volume histograms.
Although these publications contain a comprehensive review of scientific papers 
of the information published in order to be a guide for clinicians, the use of this 
guide cannot substitute for the judgment of the radiation oncologist clinician, 
considering the large number of intrinsic and extrinsic factors on which the radio-
sensitivity of each organ depends [7, 8].
There is no model that accurately predicts normal tissue responses to irradiation 
for routine clinical use, most models being more descriptive than predictive. The 
use of the multi-leaf collimator (MLC) allowed a better dosimetric coverage of the 
target volumes also offering a significant reduction in the irradiation of the healthy 
tissue from the proximity of tumors.
  (BED) = n ∙ d (1 +  d _ α / β) (1)
The isoeffect formula for conversion to standard fractionation is commonly used 
in cases where another fractionation scheme (hypofractionation or hyperfraction-
ation) is used to assess the toxicity risk according to the “QUANTEC” data:
  (EQD2) = D  
d +  (α / β) 
 _
2 +  (α / β) 
(2)
The α/β index is calculated based on information from cell survival curves 
on in vitro cell cultures, assigning values for the α/β ratio, and using these values 
to calculate a normal dose of tissue tolerance may be risky in estimating clinical 
complications [2, 7, 9].
Organs at risk (OAR) are those organs that if irradiated can be structurally and 
functionally affected. The structures that are in the proximity of the irradiated 
volume or by their anatomical function are defined as OAR, receive a certain dose 
during the treatment. These OAR’s have been divided from the radiobiological/
functional point of view into serial organs and parallel organs. The spinal cord is the 
most relevant example of OAR with serial architecture. Each subunit of the spinal 
cord is vital to the functioning of the entire organ. The parallel structural organiza-
tion is based on the functional independence of the subunits. The impairment of a 
limited number of structures does not compromise the function of the whole organ; 
the dysfunction occurs if a large number of subunits have been affected, because 
the remaining functional ones do not have sufficient compensatory capacity. An 
example of an organ with parallel architecture would be that of the parotid glands. 
In these cases the average dose absorbed throughout the organ is the most signifi-
cant predictor of toxicity [5, 7, 8].
Using a Lyman mathematical model and the algorithm proposed by Kutcher 
and collaborators, a radiobiological model was proposed based on extrapolation 
of Emami guides to any dosimetric distribution, using dose-volume histograms 
(DVH). The Lyman-Kutcher-Burman (LKB) model was and is one of the most 
used radiobiological mathematical models, but the multitude of factors involved 
in producing toxicities made this model an ideal one, without being implemented 
in clinical practice as a standard. The QUANTEC is one of the most valuable 
analyzes on dose-volume parameters based on numerous retrospective studies. 
However, the therapeutic and technical diagnostic advances in the multimodal 
treatment of the pathological pathology make it necessary to update and validate 
new recommendations regarding the dose-volume parameters correlated with 
toxicities [7–10].
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With the implementation of inverse planning techniques (IMRT and volumetric 
intensity-modulated volumetric arc therapy (VMAT)), it became necessary to 
define a risk-exposed volume (RVR) in order to obtain an optimal dose distribu-
tion using the planning software, trying to limit the risk of developing high-dose 
regions outside the target volume. ICRU83 defines RVR as the difference between 
the volume included in the external contour and the volumes CTV and OAR. With 
the implementation of IMRT, the dose received by RVR can be a predictor of the 
risk of radioinduced carcinogenesis, and a reduction of large volumes receiving 
low doses is necessary. In fact, there are numerous intrinsic and extrinsic factors 
that influence the radiosensitivity of each tissue/organ, related to the patient (age, 
comorbidities, Karnofsky score/ECOG performance status) and dependent on the 
radiosensitivity of each organ (serial dose-effect organization, the most eloquent 
case being of the spinal cord, parallel radiobiological organization volume-effect 
structure as in the case of liver and lungs, mixed serial and parallel organization 
described in the literature in the case of kidneys), but it is also influenced by the 
previous treatments applied. Radiotherapy treatment influences the response of 
radiosensitive organs by parameters as the maximum dose, average, minimum, 
dose rate, general treatment time, irradiation beam energy, and irradiated volume. 
Systemic treatments (radiosensitizing and radioprotective agents, chemotherapy, 
biological and immunotherapy) influence the tissue radiosensitivity and determine 
the variability of the different responses at the same irradiation dose. The most 
recent studies show the involvement of molecular and genetic profiles in radiosen-
sitivity. According to Emami and QUANTEC studies, cerebral radionecrosis usually 
occurs late from 3 months up to a few years after radiotherapy with initially a 5% 
risk at 5 years after treatment at a dose of 60 Gy received by one-third of the brain 
by standard fractionation. Using the ratio  α / β = 3 in formulas derived from the 
quadratic linear model, radiation necrosis was estimated at <3% for a dose <60 Gy, 
increasing to 5% if the brain tissue received dose is 72 Gy. The toxicity caused by the 
irradiation of the brainstem can be potentially lethal. The Emami study considered 
TD 5/5 of 50 Gy for the entire brainstem and 60 Gy in one-third of the brainstem 
as the tolerance limit, but reviewing the study literature evaluates a brain stem 
tolerance up to 54 Gy with <5% risk of brainstem necrosis or neurological toxicity. It 
is also recommended to limit doses up to 59 Gy per volume (1–10 cc). In exceptional 
situations the brainstem can tolerate up to 59 Gy (<< 1 cc) and can receive up to 
64 Gy [2, 8, 11].
Toxicity by spinal cord irradiation is also severe, and myelopathy is often 
disabling. For a ratio α / β = 0.87, the risk of myelopathy is 0.2% at 50 Gy and 5% at 
59.3 Gy, using the quadratic linear model. The values  used in the literature for the  
 α / β ratio are usually higher and make necessary to convert the dose of treatment per 
fractions to 2 Gy [8, 9, 12].
Radiation-induced optic neuropathy (RION) is severe toxicity leading to a rapid 
assessed blindness. Emami’s recommendations are TD 5/5 of 50 Gy for the entire organ.
Based on the QUANTEC review, a dose of 50 Gy received by the whole organ 
is associated with <1% risk of toxicity, and the risk increases from 3–7% for doses 
between 55 and 60 Gy, the increase in toxicity rate being significant for doses 
greater than 60 Gy [2, 7, 8].
For the radiotherapy of thoracic tumors, radiation-induced pneumonitis is one 
of the most common toxicities in patients treated with radiation for cancers of the 
lung, breast, and other mediastinal tumors, often being the dose-limiting toxicity. 
Parameter V20 was identified as the most significant predictor of pneumonitis.
Radiation-induced pericarditis is associated with increased levels of mortality, 
the most relevant cardiac toxicity of irradiation. It was considered that the peri-
carditis risk is less than 15% when the mean pericardial dose was <26Gy, another 
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dosimetric constraint considered predictive for pericarditis being V30 (pericar-
dium) <46% in the case of breast cancers irradiation [2, 7].
Radiation-induced liver disease (RILD) usually occurs between 2 weeks and 
3 months after radiation therapy. Emami guideline estimates an associated risk of 
<5% toxicity for an average dose of ≤30 Gy received by the liver, with a reduction to 
a maximum of 28 Gy required in patients with pre-existing liver disease.
Radiation-induced renal dysfunction is manifested in a variety of ways, from 
clinical symptoms to biochemical or imaging changes, most commonly with 
decreased creatinine clearance or even renal failure. An average dose of 18 Gy is 
considered to be associated with a 5% risk of toxicity at 5 years, with limitation to an 
average dose of 20 Gy being considered a feasible option in clinical practice [2, 5, 7].
Treatment toxicity for pelvine tumors includes femoral neck and head necrosis, 
associated with possible fracture. Factors such as osteoporosis and androgen treat-
ment in the background increase the risk of irradiation toxicity. A 52 Gy dose for 
the entire femoral head was considered the recommended limit according to Emami 
publication, limiting the dose below 50 Gy and reducing the risk of neck/femoral 
neck necrosis to <5%. However, there are studies that report toxicities for large 
doses delivered on smaller volumes [7, 9, 13].
Without proposing to present all the recommendations of these guides, we have 
exemplified some recommendations and their predictive value on the toxicities for 
radiotherapy of tumors of the cervical, thoracic, abdominal, and pelvic regions.
The development of mathematical models in cancer biology and radiotherapy 
treatment is a step motivated by the desire to evaluate the probability of tumor 
control and the probability of healthy tissue complications. The technical evolu-
tion of radiotherapy and the complexity of the treatment plans have led to the 
emergence of increasingly complex treatment plans, with unpredictable difficulty 
to evaluate dose distributions. The desire to obtain an optimal plan and to increase 
the tumor control, limiting the risk of complications at the lowest possible level, 
has oriented the research toward the development of radiobiological models with 
a predictive value of the tumor response and the toxicity rate. The development 
of radiobiological models originated three decades ago, but in recent years efforts 
have been intensified to introduce these models into clinical practice. The inability 
to consider variables as clinical data and histological type of tumor made it difficult 
to introduce these models as standard in the process of evaluating treatment plans. 
However, some producers have included radiobiological models in commercial 
TPS that use DVH curves in the treatment plan and biological parameters such 
as histologic type and characteristics of nearby healthy tissues to calculate tumor 
control probability (TCP) and normal tissue complication probability (NTCP). The 
radiobiological models included in the TPS software are based on the Poisson TCP 
model and the LKB model for the calculation of NTCP [9, 14].
Although not yet implemented as a standard of assessment in clinical routine, 
TCP and NTCP models offered the radiation oncologist and medical physicist a 
useful tool in evaluating treatment plans and selecting the best treatment plan 
but also in evaluating geometrical errors and in comparison of the most modern 
radiotherapy techniques.
Dosimetric comparisons between treatment plans have been used extensively 
in validating treatment plans generated by the inverse planning techniques IMRT 
and VMAT, determining according to EMAMI/QUANTEC recommendations and 
the latest RTOG recommendations the possibility of reducing the risk of toxicities 
associated with irradiation. The use of radiobiological models has shown a small 
benefit in TCP and a significant reduction of NTCP when using the IMRT technique 
in prostate cancer radiotherapy. TCP/NTCP models were also used to compare 
sequential IMRT plans with SIB-IMRT plans. The use of the boost integrated in the 
Translational Research in Cancer
6
VMAT technique demonstrated the ability to reduce the average dose received by 
the rectum and bladder by 13 and 17% [2, 7, 15].
Also the use of radiobiological models can highlight the percentage with which 
the TCP value increases by increasing the dose to a certain value. In the case of com-
parative VMAT single-arc vs. VMAT double-arc treatment plans, the use of NTCP 
radiobiological models revealed similar values  regarding the risk of radionecrosis of 
the femoral heads, on irradiation plans for prostate cancer although the dosimetric 
distribution is significantly different between the two plans. However, some authors 
report lower mean NTCP values  for VMAT double-arc plans.
Biological optimization based on NTCP of treatment plans has become a feasible 
alternative, based on dose-volume optimization, demonstrating the possibility to 
reduce up to 3 times the doses received by the parotid glands in the case of locally 
advanced nasopharynx cancers treated by IMRT technique [16, 17].
Patient repositioning based on imaging guidance is routinely performed in most 
radiotherapy centers using modern radiotherapy techniques using daily setup and 
four-dimensional computer tomography (CBCT) images performed with onboard 
imaging (OBI) systems which are increasingly used to compare planned and treated 
target volumes. TCP and NTCP radiobiological models can be used to evaluate the 
effect of systematic and random errors on the probability of tumor control and on 
the risk of toxicity, using information from the DVH curves. Some authors have 
used EPID portal dosimetry to check the dose received by critical organs as heart 
for the purpose of evaluating NTCP [2, 16–18].
Another direction of interest was the evaluation with the help of the NTCP of 
the advantage of the new four-dimensional computer tomography (4D-CT) tech-
nology in radiotherapy planning. The radiobiology studies proved a minor benefit 
in TCP in many situations. This evaluation has the role to give a suggestive image of 
the situations in which the 4D-CT technique offers a clear advantage over 3D image-
based planning. Reposition during treatment is made according to the geometric 
variations of the target volumes and to the changes in the anatomical conformation 
of the body. The adjustments in treatment position using CBCT imaging is often 
used without being able to accurately estimate the consequences from the point of 
view of toxicities and tumor control [2, 18–20].
Currently, replanning of treatment using weekly CBCT imaging for radiother-
apy patients can be done during the course of treatment, to provide a more accurate 
dose and to avoid erroneous treatment due to daily movement of organs. Adaptive 
radiation therapy is defined as changing the radiological treatment plan delivered 
to a patient during a course of radiation therapy to take into account temporal 
changes in anatomy, such as tumor contraction, weight loss, or internal movement, 
etc. However, the biological consequences of this intervention during the course of 
treatment may remain unclear to some practitioners. The clinical impact of adaptive 
radiotherapy has been evaluated using biological modeling of bladder cancer. In the 
Wright et al. study, various adaptive planning target volumes (PTV) were generated 
from the inter-fractional variation of the bladder observed in the first four CBCT 
sessions. In addition to IMRT plans that deliver 60 Gy to a given PTV, simultaneous 
integrated impulse (SIB) plans have been generated. For uniform clonogenic cell 
density throughout the bladder, TCP ranged from 53–58% for 60 Gy planes, while 
it was between 51 and 64% for SIB planes. They showed that dose tracking and TCP 
calculation can provide additional information on standard criteria, such as geo-
metric coverage for selected cases [20–23].
It is assumed that the use of IGRT can lead to an improvement in TCP by increas-
ing the PTV dose coverage in daily treatment while decreasing NTCP by using low 
uncertainty CTV-PTV margins in the case of prostate cancer radiotherapy, demon-
strating the ability to improve therapeutic for both IMRT and 3D-CRT plans.
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With all the efforts made to develop radiobiological models, they remain ideal 
models. Including the individual biological parameters of the patients in the 
treatment decision will contribute to the understanding of differentiated response 
of tumors to radiotherapy and will be able to transform these models into feasible 
models applicable in clinical practice. The number of malignant stem cells and their 
intrinsic cell radiosensitivity, cell repopulation, tumor and tissue hypoxia, and the 
ability of tumor cells to reoxygenate and repair DNA damage are factors whose 
introduction into the radiobiological mathematical models will increase the accu-
racy of each case of tumor control and toxicity predictions. Thus, a step forward 
will be taken in the use of these models in clinical practice within the concept of 
personalized medicine, modulating the treatment for each patient in order to obtain 
the best therapeutic ratio.
Identifying new biomarkers to guide radiotherapy tailored to each case depend-
ing on the radiosensitivity of tumor cells and healthy tissue requires the identifica-
tion of a large number of pre-therapeutic factors with predictive value on tumor 
toxicity and control. If the data obtained from the tumor histology and the patient 
performance status and comorbidities are taken into account in the evaluation and 
pre-therapeutic optimization of the plans, the biological parameters of the tumor 
are rarely considered in the modulation of the treatment. Also, early response to 
imaging-evaluated therapy may be a predictive factor of tumor control [2, 23–25].
The development, validation, and integration of imaging biomarkers using CT, 
PET-CT, and MRI to improve the response to radiotherapy are part of the areas of  
interest of clinical and preclinical studies, this research directive being integrated 
under the name of “radiomics.” There are two directions for using predictive 
biomarkers for individualized treatment, to choose the treatment offered to a 
patient (e.g., intensifying and choosing a multimodal therapy for a hypoxic tumor 
with radiation and chemotherapy resistance factors or de-escalating treatment 
for tumors with radiosensitivity-associated factors such as HPV viral etiology for 
head and neck cancers). The modulation of the treatment by altered therapeutic 
and fractional associations (hypo- and hyperfractionation) aims to obtain a higher 
TCP with the limitation of NTCP of the tissues from the vicinity of target volumes, 
avoiding the risk of toxicity [2, 24, 26, 27].
Biomarkers can also be used for early evaluation of therapeutic outcomes to 
decide whether to discontinue or continue a therapeutic procedure or modify 
the initial treatment, but validating some biomarkers and including them in 
radiobiological models that are part of the clinical decision algorithm is still a 
strategy used only in preclinical and clinical studies. Regarding systemic therapy 
significant progress has been made, by discovering new therapeutic targets that 
have changed the clinical oncological practice, making it necessary to identify 
biomarkers to guide the therapeutic decision. HER-2 and hormone receptor status 
evaluated at breast cancer patient biopsy is currently used for therapeutic proto-
col decision, EGFR mutation targets treatment for targeted molecular therapy in 
lung cancer, KRAS mutational status is integrated into colorectal cancer treatment 
to allocate patients for anti-EGFR therapies for KRAS wild-type tumors, PD-L1 
expression becomes a marker of response to immunotherapy in more and more 
nonplastic locations, and even though we have presented only a few suggestive 
examples, there is an increasing number of biomarkers with potential predictive 
for response to radiotherapy [2, 5, 27, 28].
Radiation oncology has a long history of research into understanding the implica-
tions of genetics in the variation of the response to treatment for each patient in order 
to personalize the therapy. The identification of new biological signaling pathways 
will explain the variation in the individual response of some tumors to irradiation. 
The use of elements from the genetic signature of each patient could constitute 
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biomarkers of the clinical response to irradiation by modifying radiosensitivity of the 
tumor and healthy tissue. Since 1936 the different effects for subjects of irradiation 
with an identical radiation dose have been demonstrated by the occurrence of early 
skin toxicity, the near-Gaussian frequency distribution of individual sensitivity being 
highlighted. Subsequent research has shown the involvement of genetic syndromes 
in the early onset of toxicities, with the subtraction of cell hypersensitivity to irradia-
tion, caused by affecting the DNA chain repair mechanisms. In addition to the ATM 
gene associated with ataxia-telangiectasia syndrome, other genes such as NBS1, LIG4, 
and MRE11 have been linked with syndromes associated with high radiosensitivity, 
caused by impaired DNA chain repair mechanisms [29, 30].
Modern radiobiology research has highlighted the applicability of genomics in 
predicting the adverse effects of radiotherapy, based on the application of genomics 
in radio-oncology. Advances in high-throughput approaches will support increased 
understanding of radiosensitivity and the development of future predictive analy-
ses for clinical application. There is an established contribution of genetic risk 
factor to adverse radiotherapy reactions. The radiosensitivity of an individual is 
an inherited polygenic feature, and in order to elucidate the genomic involvement 
in radiosensitivity, the Radiogenomics Consortium was set up to allow large data 
cohorts for research development, and the REQUITE project would collect stan-
dardized and genotyped data for∼5000 patients [34]. Linking their information 
with the dosimetric data will lead to the generation of multivariable models that can 
be used in the clinic, identifying new genes that have an impact on the radiosen-
sitivity of the toxicity pathogenesis and the tests that will be incorporated into the 
clinical decision-making process [30, 31].
The development in the last decades of imagistic techniques and their non-
invasive or minimally invasive character allowed the dynamic evaluation of the 
changes of the biological characteristics of the tumor. Molecular imaging brings 
pre-treatment information but also has the ability to evaluate the changes produced 
by the treatment since the first irradiation fractions. CT and MRI imaging already 
has a significant role in radiotherapy planning, CT simulation becoming a standard, 
and MRI imaging contributes to a more precise delineation of tumor invasion into 
adjacent organelles. The increasing use and availability of PET-CT imaging and 
its inclusion in treatment planning make it possible to use different tracers as a 
biomarker of tumor radiosensitivity in click practice [38]. 18F-Fluorodeoxyglucose 
(18F-FDG) is one of the most used biomarkers in experimental and clinical inves-
tigations, the SUV values  before and during the treatment being investigated as 
possible biomarkers of the treatment by chemotherapy and radiotherapy. The 
concept of “biological dose painting” is based on the delimitation of target volumes 
on functional criteria; the irradiation of a tumor with different doses and the esca-
lation of the doses in areas with high uptake of 18F-FDG were discussed with the 
introduction of IMRT and VMAT techniques that allow the irradiation with differ-
ent doses of some subvolumes from the target volume. 18F-FDG can identify tumor 
regions with high cell density and radioresistant regions due to hypoxia. Identifying 
the most common relapses after radiotherapy in the areas with higher uptake of 
18F-FDG is a new argument for dose escalation in these regions.
The observation that in several cases of locally advanced cancers the tumor 
control after irradiation was not satisfactory made necessary a careful analysis of 
the areas where recurrence occurs. The analysis of the characteristics of the tumors 
with recurrence risk revealed an increased risk for the hypoxic regions or with an 
increased number of clonogens with proliferation capacity. One of the strategies 
used to control the tumor response is to use the boost on subvolumes with radiore-
sistance pattern, considering the results of the studies that prove the survival rates 
associated with better locoregional control [32, 33].
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The use of routine boost for all patients is a controversial topic. For head and 
neck cancers and for prostate cancer, there was a benefit in escalating doses by 
10–20% in the topographic regions of the tumor with an increased risk of recur-
rence. An EORTC trial shows a minor benefit of breast boost but with a significant 
increase in toxicity rate.
Using radiobiological models, an increase of up to 20% of the TCP was observed in 
the case of a 10–30% dose escalation on a sub-volume of 60–80% of the primary tumor 
target volume. The introduction of IGRT and PET-CT hybrid imaging opens the hori-
zons of a new challenge, the topographic identification of the region where the boost 
will be made, based on the clinical rationale balancing the benefit and the toxicities.
Adaptive risk optimization uses a biological objective function instead of an 
objective function based on dose-volume constraints, maximizing TCP for differ-
ent regions of the tumor with recurrent risk while also minimizing NTCP for risk 
organs [2, 26, 35].
The tendency to include biological information in radiotherapy will lead to the 
use of cellular, molecular, and physiological characteristics in the treatment plan-
ning. PET-CT radiotracers 18F-FMISO-PET,60Cu-ATSM-PET, and blood oxygen 
diffusion (BOLD)-MRI are frequently investigated in translational research related 
to tumor hypoxia. Investigation of tumor proliferation proved benefits from 
18F-labeled fluorotime (FLT) as a biomarker.
The development of multivariable radiobiological models and dose prescription 
protocol based on functional data obtained from hybrid imaging is part of the tendency 
to include modern radiotherapy in the precision medicine trend, exploiting variations in 
tumor radiosensitivity and healthy tissues in clinical practice [2, 21, 36, 37].
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